Stifel Financial Corp Sells 137,243 Shares of Omeros Co. (NASDAQ:OMER)

Stifel Financial Corp lowered its stake in shares of Omeros Co. (NASDAQ:OMERFree Report) by 6.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,890,674 shares of the biopharmaceutical company’s stock after selling 137,243 shares during the period. Stifel Financial Corp owned 3.01% of Omeros worth $6,183,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Ancora Advisors LLC lifted its stake in Omeros by 23.1% in the third quarter. Ancora Advisors LLC now owns 210,023 shares of the biopharmaceutical company’s stock valued at $613,000 after acquiring an additional 39,475 shares during the last quarter. Barclays PLC lifted its stake in Omeros by 51.2% in the 3rd quarter. Barclays PLC now owns 45,629 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 15,456 shares during the last quarter. SG Americas Securities LLC lifted its stake in Omeros by 59.3% in the 4th quarter. SG Americas Securities LLC now owns 30,438 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 11,333 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in Omeros by 200.0% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 30,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 20,000 shares during the period. Finally, Coldstream Capital Management Inc. raised its stake in Omeros by 42.1% in the fourth quarter. Coldstream Capital Management Inc. now owns 28,130 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 8,335 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Analysts Set New Price Targets

OMER has been the topic of a number of recent analyst reports. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a report on Friday, May 17th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Tuesday, June 4th.

View Our Latest Stock Analysis on Omeros

Omeros Stock Down 1.3 %

Shares of NASDAQ:OMER opened at $3.86 on Friday. Omeros Co. has a 12-month low of $0.92 and a 12-month high of $7.72. The business has a 50 day moving average of $3.46 and a 200-day moving average of $3.47. The stock has a market cap of $223.66 million, a PE ratio of -1.96 and a beta of 1.36.

Omeros (NASDAQ:OMERGet Free Report) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.13). Equities research analysts expect that Omeros Co. will post -1.81 earnings per share for the current year.

About Omeros

(Free Report)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Featured Articles

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMERFree Report).

Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.